Skip to main
NGNE
NGNE logo

Neurogene Inc (NGNE) Stock Forecast & Price Target

Neurogene Inc (NGNE) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 25%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

Neurogene Inc. has demonstrated improved confidence in its product pipeline, particularly with its lead candidate NGN-401 for Rett syndrome, bolstered by enhanced management strategies addressing HLH reactions. Management's advancements in the monitoring of HLH via ferritin levels suggest that potential future trials can effectively address safety concerns, paving the way for more favorable clinical outcomes. This optimism translates into an increased valuation of Neurogene's prospects, with expectations of successful enrollment and significant efficacy in upcoming registrational trials influencing a positive financial outlook.

Bears say

Neurogene Inc faces significant challenges that may adversely affect its financial health, primarily stemming from the risk of clinical failures in key drug candidates, such as NGN-401 for Rett syndrome and NGN-101 for CLN5 Batten disease. Investor sentiment regarding drug pricing, mergers and acquisitions, and overall sector valuations further complicates the financial outlook, potentially leading to difficulties in raising capital. Additionally, risks related to trial delays and the generation of unfavorable clinical data could exacerbate financial uncertainty, resulting in scenarios where investor confidence wanes significantly.

Neurogene Inc (NGNE) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 25% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Neurogene Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Neurogene Inc (NGNE) Forecast

Analysts have given Neurogene Inc (NGNE) a Buy based on their latest research and market trends.

According to 4 analysts, Neurogene Inc (NGNE) has a Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $42.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $42.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Neurogene Inc (NGNE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.